Physician profile
Seth Braunstein
NPI 1427080720
$133,680.15
in general payments reported to CMS, 2019-2025
57 companies · $2,768 in 2025
The $2,768 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $22K · 2021: $16K · 2022: $1,855 · 2023: $2,371 · 2024: $2,622 · 2025: $2,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,718 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,717.81 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $77,251.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $41,724.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $3,040.28 | 2019 | |
| Lilly USA, LLC | $1,737.27 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,097.45 | 2019-2025 | Jardiance |
| Abbott Laboratories | $991.28 | 2019-2025 | Freestyle Libre 3, Octrode |
| Amgen INC. | $902.07 | 2019-2025 | Tepezza, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $763.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $567.41 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $544.20 | 2021-2025 | |
| Antares Pharma, INC. | $482.43 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $341.83 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $338.72 | 2019-2025 | |
| Corcept Therapeutics | $305.85 | 2019-2025 | Korlym |
| Radius Health, INC. | $293.57 | 2019-2025 | Tymlos |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $271.43 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $251.15 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $248.91 | 2020-2025 | Tirosint, Licart, Licart |
| Cequr Corporation | $212.79 | 2022-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $175.49 | 2022-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $156.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.45 | 2024-2025 | |
| Abbvie INC. | $146.31 | 2019 | |
| Recordati_rare_diseases_inc. | $142.93 | 2023-2025 | Isturisa, Signifor Lar |
| Tolmar, INC. | $140.80 | 2025 | Jatenzo |
| Pfizer INC. | $131.07 | 2019-2024 | |
| Eisai INC. | $114.91 | 2019 | |
| Averitas Pharma INC. | $86.27 | 2023-2025 | Qutenza |
| Valeritas, INC. | $69.43 | 2019 | |
| Esperion Therapeutics, INC. | $61.51 | 2021-2025 | Nexletol |
| Ascendis Pharma Endocrinology INC | $60.36 | 2025 | Yorvipath |
| Regeneron Healthcare Solutions, INC. | $59.07 | 2019 | |
| Azurity Pharmaceuticals, INC. | $59.00 | 2023-2025 | Adthyza, Azmiro |
| Ultragenyx Pharmaceutical INC. | $55.17 | 2019-2020 | |
| Dexcom, INC. | $53.31 | 2019-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $52.08 | 2021-2025 | Inceptiv |
| Astellas Pharma US INC | $51.93 | 2023-2025 | Veozah |
| Senseonics, Incorporated | $51.00 | 2019-2020 | |
| Sequel Med Tech, LLC | $48.38 | 2025 | Twiist |
| Beta Bionics, INC. | $45.71 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Rhythm Pharmaceuticals, INC. | $43.26 | 2023-2025 | Imcivree, Imcivree |
| Kyowa Kirin, INC. | $41.58 | 2023-2025 | Crysvita |
| Shire North American Group INC | $38.05 | 2019 | |
| Chiesi USA, INC. | $35.62 | 2024-2025 | Mycapssa |
| Halozyme INC | $33.47 | 2023 | |
| Acella Pharmaceuticals, LLC | $28.69 | 2023-2024 | NP Thyroid 60 |
| Nalpropion Pharmaceuticals LLC | $26.51 | 2019 | |
| Neurocrine Biosciences, INC. | $22.16 | 2024 | |
| Verity Pharmaceuticals INC. | $17.92 | 2025 | Tlando |
| Soleno Therapeutics, INC. | $17.54 | 2025 | Vykat Xr |
| Vivus LLC | $17.18 | 2019 | |
| Boston Scientific Corporation | $16.68 | 2019 | |
| Horizon Therapeutics Plc | $13.91 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $13.43 | 2019 | |
| Aytu Biopharma, INC. | $11.51 | 2019 | |
| Companion Medical, INC. | $11.49 | 2019 | |
| Gilead Sciences, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Braunstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.